HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer

被引：0
|
作者：
Zou, Y. [1 ]
Deng, X. [1 ]
Xie, J. [1 ]
Zeng, Y. [2 ]
Jing, B. [1 ]
Fu, J. [1 ]
Jiang, Y. [1 ]
Tang, H. [1 ]
Liu, P. [1 ]
Xie, X. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, Guangzhou, Peoples R China
[2] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
37MO
引用
收藏
页码：S1418 / S1418
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy
    Paulissen, Jeroen Hendrikus Jacobus
    van Schoonhoven, Alexander Victor
    Olin, Emma
    Postma, Arjan Jacobus
    Mbanya, Zacharie
    Dunton, Kyle John
    Postma, Maarten Jacobus
    van Hulst, Marinus
    Freriks, Roel Donald
    ADVANCES IN THERAPY, 2025, 42 (01) : 322 - 333
  • [32] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [33] Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
    Jourdain, Hugo
    Desplas, David
    Mansouri, Imene
    Zureik, Mahmoud
    Di Meglio, Antonio
    Haddy, Nadia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 531 - 531
  • [35] New drugs approval: Trastuzumab- deruxtecan-HER2-low metastatic breast cancer
    Gorgeu, Violaine
    Grellety, Thomas
    BULLETIN DU CANCER, 2023, 110 (06) : 597 - 598
  • [36] Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
    Wolf, Benita
    Dunet, Vincent
    Dubruc, Estelle
    Dolcan, Ana
    Lalonde, Marie Nicod
    Schiappacasse, Luis
    Zaman, Khalil
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1425 - 1435
  • [37] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial
    Perez-Garcia, Jose Manuel
    Batista, Marta Vaz
    Cortez-Castedo, Patricia
    Borrego, Manuel Ruiz
    Cejalvo, Juan Miguel
    de la Haba-Rodriguez, Juan
    Garrigos, Laia
    Racca, Fabriccio
    Servitja, Sonia
    Blanch, Salvador
    Gion, Maria
    Nave, Monica
    Fernandez, Adela
    Martinez-Bueno, Alejandro
    Llombart-Cussac, Antonio
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cortes, Javier
    Braga, Sofia
    CANCER RESEARCH, 2023, 83 (05)
  • [39] The Real-World Clinical Outcomes of Heavily Pretreated HER2+and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
    Lazaratos, Anna-Maria
    Dankner, Matthew
    Hamouda, Aalya
    Labidi, Soumaya
    Cohen, Victor
    Panasci, Lawrence
    Friedmann, Jennifer E.
    Patenaude, Francois
    Ferrario, Cristiano
    Basik, Mark
    Rose, April A. N.
    Fallah, Parvaneh
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [40] A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
    O'Shaughnessy, Joyce
    Basho, Reva
    Lustberg, Maryam
    Lyman, Gary H.
    Prahladan, Manoj
    James, Gareth D.
    Varghese, Della
    Lujan, Flavia
    Tesch, Hans
    CANCER RESEARCH, 2024, 84 (09)
12345